Reviewing Daiichi Sankyo (DSNKY) and Its Rivals

Daiichi Sankyo (OTCMKTS:DSNKY) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Daiichi Sankyo to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, earnings, dividends, profitability and valuation.

Dividends

Daiichi Sankyo pays an annual dividend of $0.34 per share and has a dividend yield of 1.9%. Daiichi Sankyo pays out 34.7% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 49.4% of their earnings in the form of a dividend.

Insider & Institutional Ownership

32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Daiichi Sankyo and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Daiichi Sankyo	$14.10 billion	$1.72 billion	18.52
Daiichi Sankyo Competitors	$5.42 billion	$3.22 billion	547.98

Daiichi Sankyo has higher revenue, but lower earnings than its competitors. Daiichi Sankyo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Daiichi Sankyo and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daiichi Sankyo	1	1	0	0	1.50
Daiichi Sankyo Competitors	7768	13854	25722	1032	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.50%. Given Daiichi Sankyo’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Daiichi Sankyo has less favorable growth aspects than its competitors.

Risk & Volatility

Daiichi Sankyo has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Daiichi Sankyo’s competitors have a beta of -4.20, indicating that their average share price is 520% less volatile than the S&P 500.

Profitability

This table compares Daiichi Sankyo and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daiichi Sankyo	10.92%	14.35%	6.10%
Daiichi Sankyo Competitors	-2,372.26%	-220.09%	-16.01%

Summary

Daiichi Sankyo competitors beat Daiichi Sankyo on 9 of the 15 factors compared.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.